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Thepresentstudyexaminedtheeﬀectofnicotine,aloneandincombinationwithvariousdrugsthatactontheCNS,onambulatory
activity, a behavioral index for locomotion, in ICR (CD-1) strain mice. Nicotine at 0.25–2mg/kg acutely reduced ambulatory acti-
vityofICRmice.Theeﬀect of nicotine was similarto that of haloperidol andﬂuphenazine but distinct from that of bupropion and
methylphenidate. ICR mice developed tolerance against the inhibitory eﬀect of nicotine on ambulatory activity when nicotine was
repeatedly administered. This eﬀect was also distinct from bupropion and methylphenidate as they produced augmentation of
their ambulation-stimulating eﬀects in ICR mice. Nicotine reduced the ambulation-stimulating eﬀects of bupropion and methyl-
phenidateaswellashaloperidolandﬂuphenazine.Takentogether,nicotineexhibitedunusualeﬀectsasapsychostimulantonamb-
ulatory activity in ICR mice.
1.Introduction
Nicotine (NIC), the primary psychoactive substance in
tobaccosmoke,producesavarietyofpsychoactiveeﬀectsand
has been believed to be a type of psychostimulant. In hu-
mans, NIC produces convulsions, tremors, and excitation of
respiration [1], elevates the arousal level [2, 3], facilitates be-
haviors and performance [4–6], and improves cognition and
attention abilities [7–10]. These eﬀects support the idea
that NIC is a type of psychostimulant. On the other hand,
other studies suggest that NIC may have depressant and/or
sedative eﬀects [11–14]. In addition, it is well known that
prolonged use of typical psychostimulants such as ampheta-
mine,methamphetamine,andcocainecausesschizophrenia-
like mental abnormalities (amphetamine (or methampheta-
mine) psychosis, and cocaine psychosis) [15–21]w h e r e a s
prolonged smoking has been known not to produce schi-
zophrenia-like psychosis. In contrast, smoking has been pro-
posed as a form of self-medication to alleviate symptoms
of schizophrenia [22–28]. The self-medication hypothesis
arose from the following observations: (1) patients with
schizophrenia frequently smoke cigarettes at a two- to four-
fold higher rate than that seen in the general population;
(2) patients with schizophrenia smoke heavier than the
normal population [29–35]; (3) patients with schizophre-
nia extract more nicotine from each cigarette than other
smokers [36]. Thus, smoking may ameliorate symptoms of
schizophrenia, and the NIC in cigarettes could contribute
to the heavy smoking that has been noted in patients with
schizophrenia. If the self-medication hypothesis for NIC in
patients with schizophrenia is true, the eﬀect of NIC in pa-
tients with schizophrenia is in striking contrast to the
eﬀects of typical psychostimulants in these patients as typical
psychostimulants usually worsen schizophrenia or produce
schizophrenia-like psychosis.
In animals, locomotion is a fundamental behavioral
index for evaluating the stimulating eﬀects of psychostimu-
lants. Typical psychostimulants such as amphetamine [37–
42], methamphetamine [43–50], and cocaine [49, 51–56]
consistently stimulate locomotion in rats and mice. In terms
of rodent locomotion, NIC may exhibit diﬀerent properties
from those of typical psychostimulants. NIC usually stim-
ulates locomotion in rats to a small degree but frequently
fails to produce locomotor hyperactivity in mice [57–66].
Although genetic factors could be involved in species and/or
straindiﬀerencesforeﬀectsofNIConlocomotioninrodents2 ISRN Pharmacology
[67], the eﬀects of NIC on rodent locomotion should largely
depend on pharmacological properties of NIC, as typical
psychostimulants consistently stimulate locomotion in any
species and/or strains of rodents. The eﬀects of NIC on loco-
motion in rodents are still controversial.
Ambulatory activity is a kind of locomotor activity for
mice and can be measured using a tilt-type ambulometer
[68]. Because eﬀects of many kinds of psychoactive drugs
havebeenevaluatedusingthis method[69–88],using ambu-
latoryactivityasabehavioralindexhasbeenwellestablished.
The present study examined the eﬀect of NIC, alone and in
combination with various CNS acting drugs, on ambulatory
activity in ICR (or CD-1) strain mice, which is one of the
popular strains for general multipurpose use.
2.MaterialsandMethods
2.1. Animals. Male ICR (CD-1) strain mice (Clea Japan,
Tokyo,Japan)aged7–10weeksandweighingbetween35and
42g were housed in aluminum cages (3mice/cage) with a
stainless-steel mesh top and paper bedding. Commercial
solid food (Clea Japan) and tap water were available ad libi-
tum. Cages were placed in a room artiﬁcially illuminated
by ﬂuorescent lamps on a 12L:12D schedule (light period:
07:00–19:00), at a room temperature of 25 ± 1◦C.
All experiments were conducted in accordance with the
guidelines of the Ethics Committee for Experimental Ani-
mals of the National Institute for Environmental Studies,
Japan.
2.2. Drugs. NIC was purchased from Nacalai Tesque (Kyoto,
Japan). Psychostimulants bupropion (BUP) and methyl-
phenidate (MP; Ritalin) were purchased from Sigma-Aldrich
(Tokyo, Japan) and Japan Ciba-Geigy (Hyogo), respectively.
CNS depressants ﬂuphenazine (FLU), haloperidol (HAL),
and nAChR antagonist mecamylamine (MECA) were pur-
chased from Sigma-Aldrich. NIC, BUP, MP, FLU, and MECA
were dissolved in saline (0.9% NaCl, Nacalai Tesque). HAL
was dissolved in 0.1% acetic acid solution (Wako Pure
Chemicals, Osaka, Japan).
2.3. Measurement of Ambulatory Activity in ICR Mice. Amb-
ulatory activity was measured using a tilt-type ambulometer
consisting of 10 bucket-like Plexiglas activity cages (20cm
in diameter) (SAM-10; O’Hara and Co., Tokyo, Japan) ([68,
89, 90], in press (DOI: 10.1016/j.ntt.2011.08.007), [91–93]).
Each activity cage is sustained by a fulcrum in the center of
the bottom of the cage; the fulcrum tilts according to hori-
zontal movement of the mouse in the activity cage. The
tilting movement of the activity cage activates microswitches
that surround the cage. The number of activations of micro-
switches during a set time is recorded, and the result is
printed.
3.ExperimentalProcedure
Experiment1. Eﬀectofasinglesubcutaneousadministration
of NIC on ambulatory activity in ICR mice.
ICR mice were placed individually in activity cages, and,
after 30min of adaptation, saline or 0.25, 0.5, 1, or 2mg/kg
of NIC was administered subcutaneously. Thereafter, ambu-
latory activity was continuously measured for 60min.
Experiment 2. Eﬀects of single subcutaneous administra-
tions of BUP, MP, HAL, or FUL on ambulatory activity in
ICR mice.
After 30min of adaptation in the activity cages, saline or
5 or 10mg/kg of BUP, 2 or 4mg/kg of MP, 0.031, 0.0625, or
0125mg/kg of HAL, or 0.625, 0.125, or 0.25mg/kg of FLU
was subcutaneously administered to ICR mice. Thereafter,
ambulatory activity was continuously measured for 60min.
Experiment 3. Eﬀect of repeated administrations of NIC,
BUP, or MP on ambulatory activity.
After 30min of adaptation in the activity cages, saline or
1mg/kg of NIC, 10mg/kg of BUP, or 4mg/kg of MP was
administered to mice, and ambulatory activity was measured
for 60min. These steps were repeated on the same mice 5
timeswith3-to4-dayintervalsandchangesofeﬀectsofthese
drugs on ambulatory activity were examined.
Experiment 4. Interaction between NIC and MECA on amb-
ulatory activity.
After 30min of adaptation in the activity cages, saline or
1mg/kg of MECA was subcutaneously administered to mice.
Ten minutes later, saline or 2mg/kg of NIC was subcuta-
neouslyadministeredtothemice,followedbymeasurements
of ambulatory activity for 60min.
Experiment5. InteractionsbetweenBUPandHALorFLUor
between NIC and BUP or MP on ambulatory activity.
After 30min of adaptation in the activity cages, saline or
0.031, 0.0625, or 0.125mg/kg of HAL or 0.0625, 0.125, or
0.25mg/kgofFLUwassubcutaneouslyadministeredtomice.
Ten minutes later, saline or 10mg/kg of BUP was subcuta-
neouslyadministeredtothemice,followedbymeasurements
of ambulatory activity for 60min.
After 30min of adaptation in the activity cages, saline or
0.25, 0.5, 1, or 2mg/kg of NIC and saline, 10mg/kg of BUP,
or 4mg/kg of MP were subcutaneously coadministered to
mice, followed by measurements of ambulatory activity for
60min.
3.1. Statistical Analysis. To eliminate diﬀerences of baseline
ambulatory activity, the activity of each animal after admin-
istration of each drug was normalized using the total activity
of the animal during the 30min adaptation period before
administration of each drug.
The time course of ambulatory activity after sin-
gle administration of NIC was initially examined using
repeated-measures analysis of variance (ANOVA). Then,
diﬀerences at each time point were examined using one-
way ANOVA, followed by Dunnett’s test. Diﬀerences in total
ambulatory activity over 1h were analyzed using one-way
ANOVA,followedbyDunnett’s test.P<0.05 wasestablished
as the level of signiﬁcance.ISRN Pharmacology 3
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Figure 1: Ambulatory activity in ICR mice after single subcutaneous administration of saline or 0.25–2mg/kg of NIC. The ﬁgure shows
normalized ambulatory activity that was obtained by normalizing the actual ambulatory measurement using total ambulatory activity
during the 30min adaptation period before administration to each mouse. (a) Time courses of ambulatory activity after subcutaneous
administration of saline or 0.25–2mg/kg of NIC. Symbols represent mean values of ambulatory activity for 10min periods, and vertical lines
indicate standard error of the mean (SEM). N = 40–100 animals per dose group. (b) Total ambulatory activity over 60min after administra-
tion of saline or various doses of NIC. Filled columns indicate mean values of total ambulatory activity for 60min, and vertical lines indicate
SEM.DatainFigure 1(a)wereanalyzedbyrepeatedmeasuresANOVA,followedbyone-wayANOVAandDunnett’stest. ∗P<0.05compared
with saline control at each time point. Data in Figure 1(b) were analyzed using one-way ANOVA, followed by Dunnett’s test. ∗P<0.05
compared with saline control.
4. Results
Experiment1. Eﬀectofasinglesubcutaneousadministration
of NIC on ambulatory activity in ICR mice.
NIC at 0.25–2mg/kg signiﬁcantly reduced the ambula-
tory activity of ICR mice (Figures 1(a) and 1(b)). The eﬀect
of NIC was dose dependent (Figure 1(b); F(4,275) = 20.1,
P<0.05)andlastedaslongas60min—Figure 1(a);r epeat ed
measures ANOVA (dose: F(4,275) = 20.1, P<0.05; time:
F(5,1375) = 61.896, P<0.05; interaction: F(20,1375) =
5.582, P<0.05).
Experiment 2. Eﬀects of single subcutaneous administra-
tions of BUP, MP, HAL, or FUL on ambulatory activity in
ICR mice.
BUP at 5–10mg/kg (Figure 2(a)) and MP at 2–4mg/kg
(Figure 2(b))stimulatedambulatoryactivityofICRmiceina
dose-dependentmanner(BUP:F(2,217) = 26.132,P<0.05;
MP: F(2,317) = 100.433, P<0.05).
HAL at 0.031–0.125mg/kg (Figure 2(c))a n dF L Ua t
0.625–0.25mg/kg (Figure 2(d)) signiﬁcantly and dose-dep-
endently reduced the ambulatory activity in ICR mice (HAL:
F(3,68) = 5.945, P<0.05; FLU: F(3,64) = 2.907, P<0.05).
Experiment 3. Eﬀect of repeated administrations of NIC,
BUP, or MP on ambulatory activity.
Repeated administration of saline to the same mice with
intervals of 3-4 days did not signiﬁcantly alter normalized
ambulatory activity of ICR mice (Figures 3(a), 3(b),a n d
3(c); F(4,595) = 2.373, P>0.05). The inhibitory eﬀect of4 ISRN Pharmacology
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Figure 2: Eﬀects of single subcutaneous administrations of 5–10mg/kg of BUP (a), 2–4mg/kg of MP (b), 0.031–0.125mg/kg of HAL (c), or
0.625–0.25mg/kg of FLU (d) on ambulatory activity in ICR mice. Results are shown using normalized values. Filled columns indicate mean
values of total ambulatory activity for 60min, and vertical lines indicate SEM. (a) N = 40–120, (b) N = 100–120, (c) N = 18, and (d) N =
16–18. ∗P<0.05 compared with saline control.
1mg/kg of NIC on ambulatory activity gradually attenuated
during repeated administration with intervals of 3-4 days
(Figure 3(a)). Analysis of variance failed to show statistical
signiﬁcance on the change of eﬀect of NIC (F(4,95) = 2.433,
P = 0.0527); however, signiﬁcant diﬀerences between saline
control and NIC observed at the ﬁrst three administrations
disappeared at the last two administrations, indicating
that the inhibitory eﬀect of NIC gradually weakened.
The ambulation-stimulating eﬀect of 10mg/kg of BUP
(Figure 3(b)) and 4mg/kg of MP (Figure 3(c))g r a d u a l l y
and signiﬁcantly increased when they were administered
repeatedly to the same mice with intervals of 3-4 days (BUP:
F(3,236) = 4.942, P<0.05; MP; F(4,494) = 10.489,
P<0.05) (Figures 3(b) and 3(c)).
Experiment 4. Interaction between NIC and MECA on amb-
ulatory activity.
NIC at 2mg/kg signiﬁcantly reduced the ambulatory
activity and 1mg/kg of MECA eliminated the inhibitory
eﬀe c to f2m g / k go fN I Co na m b u l a t o r ya c t i v i t yw h e na d -
ministered together (Figure 4; F(2,137) = 5.598, P<0.05).
Experiment5. InteractionsbetweenBUPandHALorFLUor
between NIC and BUP or MP on ambulatory activity.
HAL at 0.031–0.125mg/kg (Figure 5(a)) and 0.0625–
0.25mg/kg of FLU (Figure 5 (b)) signiﬁcantly reduced the
ambulation-stimulating eﬀect of 10mg/kg of BUP in a dose-
dependent manner (HAL: F(4,115) = 21.148, P<0.05;
FLU: F(4,185) = 15.622, P<0.05). Similarly, 0.25–2mg/kg
of NIC signiﬁcantly reduced the ambulation-stimulating
eﬀect of 10mg/kg of BUP in a dose-dependent manner
(Figure 5(c); F(5,234) = 23.778, P<0.05). The same doses
ofNICalsosigniﬁcantlyreducedtheambulation-stimulatingISRN Pharmacology 5
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Figure3:Eﬀectsofrepeatedadministrationsofsalineor1mg/kgofNIC(a),10mg/kgofBUP(b),or4mg/kgofMP(c)tothesameICRmice
on ambulatory activity. The administration was repeated 5 times with intervals of 3-4 days. Symbols represent mean values of ambulatory
activity for 60min periods after the administrations, and vertical lines indicate SEM. Saline: N = 60, NIC: N = 20, BUP: N = 60, and MP:
N = 100. ∗P<0.05 compared with saline control at the same time point. #P<0.05 compared with the ﬁrst administration of the drug.
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Figure 4: Eﬀects of combined administration of 2mg/kg of NIC
with1mg/kgofMECAonambulatoryactivity.Filledcolumnsindi-
cate mean values of total ambulatory activity for 60min after the
administrations, and vertical lines indicate SEM. Saline + saline:
N = 80, NIC + saline: N = 20, and NIC + MECA: N = 40. ∗P<
0.05 compared with NIC + saline.
eﬀe c to f4 m g / k go fM P( Figure 5(d); F(5,194) = 23.86,
P<0.05).
5. Discussion
Ambulatoryactivitymeasuredusingatilt-typeambulometer
is sensitive to vertical movement of mice in the activity cage
of the ambulometer but insensitive to vertical movement
of animals. Therefore, ambulatory activity can be used as a
measure of behavioral indices for locomotion in mice. This
notion is further supported by results of the previous [91–
93] and present studies that show the ambulatory activity
of ICR (CD-1) mice was stimulated by psychostimulants
such as BUP and MP, which have been known to stimulate
mouselocomotion[94–99],andreducedbydepressantssuch
as HAL and FLU, which have been known to reduce mouse
locomotion [98, 100–102].
The present study revealed that NIC at 0.25–2mg/kg
acutely reduced ambulatory activity in ICR mice under the
same experimental condition for evaluating eﬀects of psy-
chostimulants BUP and MP and depressants HAL and FLU.
Psychostimulants sometimes cause stereotyped or repetitive6 ISRN Pharmacology
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Figure 5: Eﬀects of combined administrations of 10mg/kg of BUP with 0.031–0.125mg/kg of HAL (a), 0.0625–0.25mg/kg of FLU (b), or
0.25–2mg/kg of NIC (c) or combined administration of 4mg/kg of MP with 0.25–2mg/kg of NIC (d) on ambulatory activity in ICR mice.
Filled columns represent mean values of ambulatory activity for 60min after the administrations, and vertical lines indicate SEM. (a) N =
20–40, (b) N = 30–50, (c) N = 20–80, and (d) N = 20–40. ∗P<0.05 compared with BUP + saline or MP + saline.
behaviors (i.e., stereotypy) that are able to cause decrease of
theambulatoryactivitymeasurementofmice.However,NIC
at 0.25–2mg/kg did not produce such eﬀect in ICR mice but
animals exhibited less activity or sedation in the bucket-like
activity cage. Because previous studies have also shown that
0.1–3mg/kg of NIC produces hypoactivity on locomotion in
ICR mice [60, 103, 104], it is possible to conclude that NIC
acutely reduces locomotion in ICR mice. This locomotor
eﬀect of NIC in ICR mice is distinct from the eﬀects of psy-
c h o s t i m u l a n t ss u c ha sB U Pa n dM P .
TheideathatNICexhibitsdistinctpropertiesonlocomo-
tor eﬀects from those of psychostimulants in ICR mice is fur-
ther supported by results in the present study that examined
eﬀects of repeated administration of NIC, BUP, and MP. It is
well established that repeated administration of psychostim-
ulants to the same animals produces augmented responses
to these agents, a phenomena referred to as behavioral sen-
sitization. BUP and MP also produce the same properties
as psychostimulants on locomotor eﬀects in rodents [105–
109], and the properties of BUP and MP were conﬁrmed
in ICR mice in the present study. On the other hand, ICR
mice developed tolerance against the inhibitory eﬀect of NIC
on the ambulatory activity when NIC was repeatedly admi-
nistered. Thus, NIC produces unusual properties as a psy-
chostimulant on locomotion in ICR mouse.
NIC exhibited eﬀects similar to depressants such as HAL
and FLU rather than psychostimulants such as BUP and
MP on locomotion of ICR mice in this study; that is,ISRN Pharmacology 7
NIC reduced the ambulatory activity of ICR mice and the
ambulation-stimulatingeﬀectsofBUPandMP.Theseresults
suggest that NIC may lead to similar eﬀects as HAL and
FLU. It has been reported that NIC is able to ameliorate
symptoms such as deﬁcits of cognition and/or attention in
animal models for psychosis as well as the eﬀects of anti-
psychotics [110–117], indicating that NIC exhibits similar
pharmacological properties to antipsychotics in animals.
Thus, the idea in which NIC produces similar eﬀects to anti-
psychoticsinrodentshasalreadybeenknown;however,ithas
not been elucidated whether this notion is true for eﬀects of
NIC on rodent locomotion. The present study revealed that
NIC exhibits similar eﬀects as antipsychotics such as HAL
and FLU on locomotion in ICR mice. Both BUP and MP
are able to induce psychosis-like illnesses in humans [118–
129], and the psychosis-like illnesses could be ameliorated
by antipsychotics such as HAL and FLU. In light of these
observations and the results of the present study, the self-
medication hypothesis for heavy smoking among patients
with schizophrenia [22–28] seems reasonable. NIC may
reduce psychomotor excitation that accompanies with schi-
zophrenia, and such eﬃcacy of nicotine may be involved in
heavy smoking in schizophrenia patients [29–35].
Neuronal acetylcholine receptors (nAChRs) could be in-
volved in the inhibitory eﬀect of NIC on ambulatory activity
in ICR mice as the nAChRs antagonist, MECA, ameliorated
the eﬀect of NIC. nAChRs are known to be involved in the
inhibitory eﬀect of NIC on locomotion in C57Bl/6 mice [63,
130]. ICR mice developed tolerance against the inhibitory
eﬀect of NIC on ambulatory activity when NIC was repeat-
edly administered. C57Bl/6 mice also develop tolerance
against the inhibitory eﬀe c to nl o c o m o t i o nw h e nN I Cw a s
chronically or repeatedly administered, and the development
of tolerance is accompanied by changes in nAChRs in the
brain[63,130].TheinvolvementofnAChRsintheinhibitory
eﬀect of NIC and in the development of tolerance against
the NIC eﬀect on locomotion in C57Bl/6 mice suggests that
nAChRs may play similar roles in locomotor eﬀects of NIC
in ICR mice.
The neurotransmitter dopamine (DA) might also be in-
volved in the eﬀects of NIC on ambulatory activity in ICR
mice. Because both BUP and MP enhance DA neurotrans-
mission through inhibition of its reuptake [96, 131–136],
changes of DA neurotransmission could be involved in the
ambulation-stimulating eﬀects of these agents. The involve-
ment of DA in the ambulation-stimulating eﬀect of BUP in
ICR mice is further supported by the present results in which
both HAL and FLU, which possess DA receptor antagonizing
abilities, reduced the ambulation-stimulating eﬀect of BUP
in ICR mice. Because eﬀects of NIC observed in the present
study were similar to those of HAL and FLU, it is probable
that NIC inﬂuences DA neurotransmission to reduce ambu-
latoryactivityandtheambulation-stimulatingeﬀectsofBUP
and MP in ICR mice. Because nAChRs are directly and/or
indirectly able to aﬀect DA neurotransmission [137–140],
interaction between nAChRs and the DA system might
account for the eﬀects of NIC on ambulatory activity in ICR
mice.
Acknowledgment
This study was supported by the Smoking Research Founda-
tion, Japan.
References
[1] A. G. Goodman, Ed., Goodman and Gilman’s The Pharmaco-
logical Basis of Therapeutics, Pergamon Press, New York, NY,
USA, 8th edition, 1990.
[2] J. E. Henningﬁeld, “Behavioral pharmacology of cigarette
smoking,” Advances in Behavioral Pharmacology, vol. 4, pp.
131–210, 1984.
[3] E.F.Domino,“Nicotine:auniquepsychoactivedrug.Arousal
with skeletal muscle relaxation,” Psychopharmacology Bul-
letin, vol. 22, no. 3, pp. 870–874, 1986.
[4] K. A. Perkins, L. H. Epstein, R. L. Stiller, J. E. Sexton,
T. D. Debski, and R. G. Jacob, “Behavioral performance
eﬀects of nicotine in smokers and nonsmokers,” Pharma-
cology Biochemistry and Behavior, vol. 37, no. 1, pp. 11–15,
1990.
[5] G. J. Spilich, L. June, and J. Renner, “Cigarette smoking and
cognitive performance,” British Journal of Addiction, vol. 87,
no. 9, pp. 1313–1326, 1992.
[6] S. J. Heishman, B. A. Kleykamp, and E. G. Singleton, “Meta-
analysis of the acute eﬀects of nicotine and smoking on hu-
man performance,” Psychopharmacology, vol. 210, no. 4, pp.
453–469, 2010.
[7] B. Hahn, T. J. Ross, F. A. Wolkenberg, D. M. Shakleya, M.
A. Huestis, and E. A. Stein, “Performance eﬀects of nicotine
during selective attention, divided attention, and simple sti-
mulus detection: an fMRI study,” Cerebral Cortex, vol. 19, no.
9, pp. 1990–2000, 2009.
[8] G. E. Swan and C. N. Lessov-Schlaggar, “The eﬀects
of tobacco smoke and nicotine on cognition and the
brain,” Neuropsychology Review, vol. 17, no. 3, pp. 259–273,
2007.
[9] A. Mendrek, J. Monterosso, S. L. Simon et al., “Working
memory in cigarette smokers: comparison to non-smokers
and eﬀects of abstinence,” Addictive Behaviors,v o l .3 1 ,n o .5 ,
pp. 833–844, 2006.
[10] M. Ernst, S. J. Heishman, L. Spurgeon, and E. D. London,
“Smoking history and nicotine eﬀects on cognitive perfor-
mance,” Neuropsychopharmacology, vol. 25, no. 3, pp. 313–
319, 2001.
[11] D. G. Gilbert, “Paradoxical tranquilizing and emotion-redu-
cing eﬀects of nicotine,” Psychological Bulletin,v o l .8 6 ,n o .4 ,
pp. 643–661, 1979.
[12] J. B. Acri, “Nicotine modulates eﬀects of stress on acoustic
startle reﬂexes in rats: dependence on dose, stressor and ini-
tial reactivity,” Psychopharmacology, vol. 116, no. 3, pp. 255–
265, 1994.
[13] D. G. Gilbert, J. H. Robinson, C. L. Chamberlin, and C. D.
Spielberger, “Eﬀects of smoking/nicotine on anxiety, heart
rate, and lateralization of EEG during a stressful movie,” Psy-
chophysiology, vol. 26, no. 3, pp. 311–320, 1989.
[14] S.B .M orissett e,M.T .T ull,S.B .G ulli v er ,B .W .K amholz,and
R. T. Zimering, “Anxiety, anxiety disorders, tobacco use, and
nicotine: a critical review of interrelationships,” Psychological
Bulletin, vol. 133, no. 2, pp. 245–272, 2007.8 ISRN Pharmacology
[15] M. Srisurapanont, S. Arunpongpaisal, K. Wada, J. Marsden,
R. Ali, and R. Kongsakon, “Comparisons of metham-
phetamine psychotic and schizophrenic symptoms: a dif-
ferential item functioning analysis,” Progress in Neuro-
Psychopharmacology and Biological Psychiatry,v o l .3 5 ,n o .4 ,
pp. 959–964, 2011.
[16] N. Kuzenko, J. Sareen, K. Beesdo-Baum et al., “Associations
between use of cocaine, amphetamines, or psychedelics and
psychotic symptoms in a community sample,” Acta Psychi-
atrica Scandinavica, vol. 123, no. 6, pp. 466–474, 2011.
[17] K. Akiyama, A. Saito, and K. Shimoda, “Chronic metham-
phetamine psychosis after long-term abstinence in Japanese
incarcerated patients,” American Journal on Addictions, vol.
20, no. 3, pp. 240–249, 2011.
[18] E. Yokobayashi, H. Ujike, T. Kotaka et al., “Association study
of serine racemase gene with methamphetamine psychosis,”
Current Neuropharmacology, vol. 9, no. 1, pp. 169–175, 2011.
[19] B. Angrist, G. Sathananthan, S. Wilk, and S. Gershon,
“Amphetamine psychosis: behavioral and biochemical as-
pects,” Journal of Psychiatric Research, vol. 11, pp. 13–23,
1974.
[20] Y. L. Tang, H. R. Kranzler, J. Gelernter, L. A. Farrer, D.
Pearson, and J. F. Cubells, “Transient cocaine-associated be-
havioralsymptomsratedwithanewinstrument,thescalefor
assessment of positive symptoms for cocaine-induced psy-
chosis (SAPS-CIP),” American Journal on Addictions, vol. 18,
no. 5, pp. 339–345, 2009.
[21] J. V. Nunes and P. A. Broderick, “Novel research translates to
clinicalcasesofschizophrenicandcocainepsychosis,”Neuro-
psychiatric Disease and Treatment, vol. 3, no. 4, pp. 475–485,
2007.
[22] A.H.Glassman,“Cigarettesmoking:implicationsforpsychi-
atric illness,” American Journal of Psychiatry, vol. 150, no. 4,
pp. 546–553, 1993.
[23] T. H. Svensson, J. Grenhoﬀ, and G. Engberg, “Eﬀect of nico-
tine on dynamic function of brain catecholamine neurons,”
Ciba Foundation Symposium, vol. 152, pp. 169–180, 1990.
[24] C.-S. Tung, J. Grenhoﬀ, and T. H. Svensson, “Nicotine coun-
teracts midbrain dopamine cell dysfunction induced by pre-
frontal cortex inactivation,” Acta Physiologica Scandinavica,
vol. 138, no. 3, pp. 427–428, 1990.
[25] M.Nisell,G.G.Nomikos,andT.H.Svensson,“Nicotinedep-
endence, midbrain dopamine systems and psychiatric disor-
ders,” Pharmacology and Toxicology, vol. 76, no. 3, pp. 157–
162, 1995.
[26] V. Kumari and P. Postma, “Nicotine use in schizophrenia: the
self medication hypotheses,” Neuroscience and Biobehavioral
Reviews, vol. 29, no. 6, pp. 1021–1034, 2005.
[27] Y. Tizabi, “Nicotine and nicotinic system in hypoglutamater-
gic models of schizophrenia,” Neurotoxicity Research, vol. 12,
no. 4, pp. 233–246, 2007.
[28] A. Olincy and K. E. Stevens, “Treating schizophrenia symp-
toms with an α7 nicotinic agonist, from mice to men,” Bio-
chemical Pharmacology, vol. 74, no. 8, pp. 1192–1201,
2007.
[29] E. Masterson and B. O’Shea, “Smoking and malignancy in
schizophrenia,” British Journal of Psychiatry, vol. 145, pp.
429–432, 1984.
[ 3 0 ]J .R .H u g h e s ,D .K .H a t s u k a m i ,J .E .M i t c h e l l ,a n dL .A .
Dahlgren, “Prevalence of smoking among psychiatric outpa-
tients,” American Journal of Psychiatry, vol. 143, no. 8, pp.
993–997, 1986.
[31] D. C. Goﬀ, D. C. Henderson, and E. Amico, “Cigarette
smoking in schizophrenia: relationship to psychopathology
and medication side eﬀects,” American Journal of Psychiatry,
vol. 149, no. 9, pp. 1189–1194, 1992.
[ 3 2 ]A .D i w a n ,M .C a s t i n e ,C .S .P o m e r l e a u ,J .H .M e a d o r -
Woodruﬀ,andG.W .Dalack,“Diﬀerentialprevalenceofciga-
rette smoking in patients with schizophrenic vs mood dis-
orders,” Schizophrenia Research, vol. 33, no. 1-2, pp. 113–118,
1998.
[33] C.KellyandR.G.McCreadie,“Smokinghabits,currentsym-
ptoms, and premorbid characteristics of schizophrenic pa-
tients in Nithsdale, Scotland,” American Journal of Psychiatry,
vol. 156, no. 11, pp. 1751–1757, 1999.
[ 3 4 ] K .L a s s e r ,J .W .B o y d ,S .W o o l h a n d l e r ,D .U .H i m m e l s t e i n ,D .
M c C o r m i c k ,a n dD .H .B o r ,“ S m o k i n ga n dm e n t a li l l n e s s :a
population-based prevalence study,” JAMA, vol. 284, no. 20,
pp. 2606–2610, 2000.
[ 3 5 ]J .D eL e o n ,M .D a d v a n d ,C .C a n u s o ,A .O .W h i t e ,J .K .
Stanilla, and G. M. Simpson, “Schizophrenia and smoking:
an epidemiological survey in a state hospital,” American Jour-
nal of Psychiatry, vol. 152, no. 3, pp. 453–455, 1995.
[36] A. Olincy, D. A. Young, and R. Freedman, “Increased levels
of the nicotine metabolite cotinine in schizophrenic smokers
compared to other,” Biological Psychiatry,v o l .4 2 ,n o .1 ,p p .
1–5, 1997.
[37] D. Li, S. Herrera, N. Bubula et al., “Casein kinase 1 enables
nucleus accumbens amphetamine-induced locomotion by
regulating AMPA receptor phosphorylation,” J o u r n a lo fN e u -
rochemistry, vol. 118, no. 2, pp. 237–247, 2011.
[38] J. J. Cortright, D. S. Lorrain, J. A. Beeler, W.-J. Tang, and P.
Vezina, “Previous exposure to Δ9-tetrahydrocannibinol en-
hances locomotor responding to but not self-administration
of amphetamine,” Journal of Pharmacology and Experimental
Therapeutics, vol. 337, no. 3, pp. 724–733, 2011.
[39] M. H. Baumann, Z. Williams, D. Zolkowska, and R. B.
Rothman, “Serotonin (5-HT) precursor loading with 5-hyd-
roxy-l-tryptophan (5-HTP) reduces locomotor activation
produced by (+)-amphetamine in the rat,” Drug and Alcohol
Dependence, vol. 114, pp. 147–152, 2010.
[40] S. R. Kameda, D. F. Fukushiro, T. F. Trombin et al., “Adoles-
centmicearemorevulnerablethanadultstosingleinjection-
induced behavioral sensitization to amphetamine,” Pharma-
cology Biochemistry and Behavior, vol. 98, no. 2, pp. 320–324,
2011.
[41] S. Gormley and P.-P. Rompr´ e, “Blockade of mGLUR5 recep-
tors diﬀerentially alters amphetamine-induced enhancement
of locomotor activity and of brain stimulation reward,” Jour-
n a lo fP s y c h o p h a r m a c o l o g y , vol. 25, no. 3, pp. 393–401,
2011.
[42] X. Fan, M. Xu, and E. J. Hess, “D2 dopamine receptor sub-
type-mediated hyperactivity and amphetamine responses in
amodelofADHD , ”NeurobiologyofDisease,v ol.37,no .1,pp .
228–236, 2010.
[43] B. A. McGuire, M. G. Baladi, and C. P. France, “Eating high-
fat chow enhances sensitization to the eﬀects of metham-
phetamine on locomotion in rats,” European Journal of Phar-
macology, vol. 658, no. 2-3, pp. 156–159, 2011.
[ 4 4 ]T .F u t a m u r a ,S .A k i y a m a ,H .S u g i n o ,A .F o r b e s ,R .D .
McQuade, and T. Kikuchi, “Aripiprazole attenuates estab-
lished behavioral sensitization induced by methampheta-
mine,” Progress in Neuro-Psychopharmacology and Biological
Psychiatry, vol. 34, no. 6, pp. 1115–1119, 2010.ISRN Pharmacology 9
[45] T. Uehara, T. Sumiyoshi, T. Seo et al., “Neonatal exposure to
MK-801, an N-methyl-d-aspartate receptor antagonist, en-
hances methamphetamine-induced locomotion and disrupts
sensorimotor gating in pre- and postpubertal rats,” Brain
Research, vol. 1352, pp. 223–230, 2010.
[ 4 6 ]D .A .H a l l ,J .P .P o w e r s ,a n dJ .M .G u l l e y ,“ B l o c k a d eo fD 1
dopamine receptors in the medial prefrontal cortex atten-
uates amphetamine- and methamphetamine-induced loco-
motor activity in the rat,” Brain Research, vol. 1300, pp. 51–
57, 2009.
[47] P. S. Cliﬀord, N. Hart, J. Thompson et al., “Prenatal lead
exposure enhances methamphetamine sensitization in rats,”
Pharmacology Biochemistry and Behavior,v o l .9 3 ,n o .2 ,p p .
165–169, 2009.
[ 4 8 ] R .L .G o o da n dR .A .R a d c l i ﬀe, “Methamphetamine-induced
locomotor changes are dependent on age, dose and geno-
type,” Pharmacology Biochemistry and Behavior, vol. 98, no.
1, pp. 101–111, 2011.
[49] J. A. Zombeck, A. D. Lewicki, K. Patel, T. Gupta, and J. S.
Rhodes, “Patterns of neural activity associated with diﬀer-
ential acute locomotor stimulation to cocaine and metham-
phetamine in adolescent versus adult male C57BL/6J mice,”
Neuroscience, vol. 165, no. 4, pp. 1087–1099, 2010.
[50] Y. Kaneko, A. Kashiwa, T. Ito, S. Ishii, A. Umino, and T.
Nishikawa, “Selective serotonin reuptake inhibitors, ﬂuoxe-
tine and paroxetine, attenuate the expression of the esta-
blished behavioral sensitization induced by methampheta-
mine,”Neuropsychopharmacology,vol.32,no.3,pp.658–664,
2007.
[51] S. Cliﬀord, R. A. Zeckler, S. Buckman et al., “Impact of food
restriction and cocaine on locomotion in ghrelin- and ghre-
lin-receptor knockout mice,” AddictionBiology, vol.16,no.3,
pp. 386–392, 2011.
[52] D. Thompson, L. Martini, and J. L. Whistler, “Altered ratio
of D1 and D2 dopamine receptors in mouse striatum is asso-
ciated with behavioral sensitization to cocaine,” PLoS ONE,
vol. 5, no. 6, Article ID e11038, 2010.
[53] K. R. Rodvelt, S. Z. Lever, J. R. Lever, L. R. Blount, K.-H. Fan,
andD.K.Miller,“SA4503attenuatescocaine-inducedhyper-
activity and enhances methamphetamine substitution for a
cocaine discriminative stimulus,” Pharmacology Biochemistry
and Behavior, vol. 97, no. 4, pp. 676–682, 2011.
[54] C.Brabant,L.Alleva,T.Grisaretal.,“EﬀectsoftheH3recep-
tor inverse agonist thioperamide on cocaine-induced loco-
motion in mice: role of the histaminergic system and poten-
tial pharmacokinetic interactions,” Psychopharmacology, vol.
202, no. 4, pp. 673–687, 2009.
[55] A. K. Stoker and A. Markou, “Withdrawal from chronic co-
caine administration induces deﬁcits in brain reward func-
tion in C57BL/6J mice,” Behavioural Brain Research, vol. 223,
no. 1, pp. 176–181, 2011.
[56] M. J. Acerbo and A. K. Johnson, “Behavioral cross-
sensitization between DOCA-induced sodium appetite and
cocaine-induced locomotor behavior,” Pharmacology Bioche-
mistry and Behavior, vol. 98, no. 3, pp. 440–448, 2011.
[57] M. J. Marks, J. B. Burch, and A. C. Collins, “Genetics of nico-
tine response in four inbred strains of mice,” Journal of Phar-
macology and Experimental Therapeutics, vol. 226, no. 1, pp.
291–302, 1983.
[58] G. B. Freeman, K. A. Sherman, and G. E. Gibson, “Locomo-
tor activity as a predictor of times and dosages for studies
ofnicotine’sneurochemicalactions,”PharmacologyBiochem-
istry and Behavior, vol. 26, no. 2, pp. 305–312, 1987.
[59] T. Kita, T. Nakashima, M. Shirase, M. Asahina, and Y. Kuro-
gochi, “Eﬀects of nicotine on ambulatory activity in mice,”
Japanese Journal of Pharmacology, vol. 46, no. 2, pp. 141–146,
1988.
[60] M. I. Damaj and B. R. Martin, “Is the dopaminergic system
involved in the central eﬀects of nicotine in mice?” Psy-
chopharmacology, vol. 111, no. 1, pp. 106–108, 1993.
[61] A. Smolen, M. J. Marks, J. C. DeFries, and N. D. Henderson,
“Individual diﬀerences in sensitivity to nicotine in mice: res-
ponse to six generations of selective breeding,” Pharmacology
Biochemistry and Behavior, vol. 49, no. 3, pp. 531–540, 1994.
[62] Y. Itzhak and J. L. Martin, “Eﬀects of cocaine, nicotine,
dizocipline and alcohol on mice locomotor activity: cocaine-
alcohol cross-sensitization involves upregulation of striatal
dopaminetransporterbindingsites,”BrainResearch,vol.818,
no. 2, pp. 204–211, 1999.
[63] J. A. Sparks and J. R. Pauly, “Eﬀects of continuous oral nico-
tine administration on brain nicotinic receptors and respon-
siveness to nicotine in C57B1/6 mice,” Psychopharmacology,
vol. 141, no. 2, pp. 145–153, 1999.
[64] H. G¨ addn¨ as, K. Pietil¨ a, and L. Ahtee, “Eﬀects of chronic oral
nicotine treatment and its withdrawal on locomotor activity
and brain monoamines in mice,” Behavioural Brain Research,
vol. 113, no. 1-2, pp. 65–72, 2000.
[65] A. Casta˜ n´ e, E. Valjent, C. Ledent, M. Parmentier, R. Maldon-
ado, and O. Valverde, “Lack of CB1 cannabinoid receptors
modiﬁes nicotine behavioural responses, but not nicotine
abstinence,” Neuropharmacology, vol. 43, no. 5, pp. 857–867,
2002.
[66] A.-S. Vill´ egier, L. Salomon, S. Granon et al., “Monoamine
oxidase inhibitors allow locomotor and rewarding responses
to nicotine,” Neuropsychopharmacology, vol. 31, no. 8, pp.
1704–1713, 2006.
[67] K. J. Gill and A. E. Boyle, “Genetic basis for the psychostim-
ulant eﬀects of nicotine: a quantitative trait locus analysis in
AcB/BcA recombinant congenic mice,” Genes, Brain and Be-
havior, vol. 4, no. 7, pp. 401–411, 2005.
[68] M. Hirabayashi, M. Iizuka, and S. Tadokoro, “Simple and
easy method for measurement of ambulatory activity in
mice,” Folia Pharmacologica Japonica, vol. 74, no. 5, pp. 629–
639, 1978.
[69] H. Kuribara and S. Tadokoro, “Development of tolerance to
ambulation-increasing eﬀect of scopolamine dependent on
environmental factors in mice,” Japanese Journal of Pharma-
cology, vol. 33, no. 5, pp. 1041–1048, 1983.
[70] H. Kuribara and S. Tadokoro, “Circadian variation in the
ambulation-increasing eﬀect of apomorphine after repeated
administration in mice,” Japanese Journal of Psychopharma-
cology, vol. 4, no. 3, pp. 231–236, 1984.
[71] T. Asami, H. Kuribara, and S. Tadokoro, “Eﬀects of repeated
administration of bromocriptine on ambulatory activity in
mice, and changes in methamphetamine sensitivity in bro-
mocriptine-experienced mice,” Japanese Journal of Psycho-
pharmacology, vol. 6, no. 3, pp. 309–317, 1986.
[72] Y. Iijima, T. Asami, and H. Kuribara, “Modiﬁcation by MK-
801 (dizocilpine), a noncompetitive NMDA receptor antago-
nist, of morphine sensitization: evaluation by ambulation in
mice,” Japanese Journal of Psychopharmacology, vol. 16, no. 1,
pp. 11–18, 1996.
[73] K. Hirate and H. Kuribara, “Characteristics of the ambu-
lation-increasing eﬀect of GBR-12909, a selective dopamine
uptake inhibitor, in mice,” Japanese Journal of Pharmacology,
vol. 55, no. 4, pp. 501–511, 1991.10 ISRN Pharmacology
[74] H. Kuribara and Y. Uchihashi, “Dopamine antagonists can
inhibitmethamphetaminesensitization,butnotcocainesen-
sitization, when assessed by ambulatory activity in mice,”
Journal of Pharmacy and Pharmacology, vol. 45, no. 12, pp.
1042–1045, 1993.
[75] H. Kuribara and Y. Uchihashi, “Eﬀects of haloperidol on the
methamphetamine sensitization: assessment by ambulatory
activity in mice,” Japanese Journal of Psychiatry and Neurol-
ogy, vol. 47, no. 3, pp. 661–668, 1993.
[76] H. Kuribara and Y. Uchihashi, “Eﬀects of dopamine antag-
onism on methamphetamine sensitization: evaluation by
ambulatory activity in mice,” Pharmacology Biochemistryand
Behavior, vol. 47, no. 1, pp. 101–106, 1994.
[ 7 7 ]H .K u r i b a r a ,T .A s a m i ,T .S a i t o ,I .I d a ,a n dS .T a d o k o r o ,
“Behavioral study on mergocriptine (CBM36-733) by ambu-
latory activity in mice: repeated administration and interac-
tion with methamphetamine,” Japanese Journal of Pharma-
cology, vol. 54, no. 2, pp. 163–170, 1990.
[ 7 8 ]H .K u r i b a r a ,T .K a t s u y a ,T .A s a h i ,a n dS .T a d o k o r o ,“ E ﬀects
of repeated administration of buprenorphine on ambulatory
activityinmice,”JapaneseJournalofPsychopharmacology,vol.
11, no. 2, pp. 123–127, 1991.
[ 7 9 ]H .K u r i b a r a ,T .A s a m i ,I .I d a ,a n dS .T a d o k o r o ,“ C h a r -
acteristics of the ambulation-increasing eﬀect of the non-
competitive NMDA antagonist MK-801 in mice: assess-
ment by the coadministration with central-acting drugs,”
Japanese Journal of Pharmacology, vol. 58, no. 1, pp. 11–18,
1992.
[80] H.Kuribara,“Canposttreatmentwiththeselectivedopamine
D2 antagonist, YM-O9151-2, inhibit induction of metham-
phetamine sensitization? Evaluation by ambulatory activity
in mice,” Pharmacology Biochemistry and Behavior, vol. 49,
no. 2, pp. 323–326, 1994.
[81] H. Kuribara, “Dopamine D1 and D2 receptor antagonists
suppress acute stimulant action of cocaine, but enhance
cocaine sensitization,” Japanese Journal of Psychiatry and
Neurology, vol. 48, no. 4, pp. 907–911, 1994.
[82] H. Kuribara, “Modiﬁcation by caﬀeine of the sensitization
to methamphetamine and cocaine in terms of ambulation in
mice,” Life Sciences, vol. 55, no. 12, pp. 933–940, 1994.
[83] H.Kuribara,“Caﬀeineenhancesthestimulanteﬀectofmeth-
amphetamine, but may not aﬀect induction of methamphe-
tamine sensitization of ambulation in mice,” Psychopharma-
cology, vol. 116, no. 2, pp. 125–129, 1994.
[84] H. Kuribara, “Eﬀects of sulpiride and nemonapride, ben-
zamide derivatives having distinct potencies of antagonis-
tic action on dopamine D2 receptors, on sensitization to
methamphetamine in mice,” Journal of Pharmacy and Phar-
macology, vol. 48, no. 3, pp. 292–296, 1996.
[85] H.Kuribara,“Modiﬁcationofmorphinesensitizationbyopi-
oid and dopamine receptor antagonists: evaluation by study-
ing ambulation in mice,” European Journal of Pharmacology,
vol. 275, no. 3, pp. 251–258, 1995.
[86] H. Kuribara, “Caﬀeine enhances acute stimulant eﬀect of
morphine but inhibits morphine sensitization when assessed
by ambulation of mice,” Progress in Neuro-Psychopharma-
cology and Biological Psychiatry, vol. 19, no. 2, pp. 313–321,
1995.
[87] H. Kuribara, “Inhibition of methamphetamine sensitization
by post-methamphetamine treatment with SCH 23390 or
haloperidol,” Psychopharmacology, vol. 119, no. 1, pp. 34–38,
1995.
[88] H. Kuribara, “Interaction between D1 and D2 antagonists in
the inhibition of methamphetamine-induced ambulation in
mice,” Pharmaceutical Sciences, vol. 2, no. 3, pp. 141–144,
1996.
[89] T. Umezu, J. Yonemoto, Y. Soma, and T. Suzuki, “Tris(2-
chloroethyl)phosphate increases ambulatory activityinmice:
pharmacological analyses of its neurochemical mechanism,”
Toxicology and Applied Pharmacology, vol. 148, no. 1, pp.
109–116, 1998.
[90] T. Umezu, A. Sakata, and H. Ito, “Ambulation-promoting
eﬀect of peppermint oil and identiﬁcation of its active con-
stituents,” Pharmacology Biochemistry and Behavior, vol. 69,
no. 3-4, pp. 383–390, 2001.
[91] T. Umezu and M. Morita, “Evidence for the involvement of
dopamine in ambulation promoted by menthol in mice,”
Journal Pharmacological Sciences, vol. 91, no. 2, pp. 125–135,
2003.
[92] T. Umezu, “Evidence for dopamine involvement in ambu-
lation promoted by menthone in mice,” Pharmacology Bio-
chemistry and Behavior, vol. 91, no. 3, pp. 315–320, 2009.
[93] T. Umezu, “Evidence for dopamine involvement in ambula-
tionpromotedbypulegone inmice,” PharmacologyBiochem-
istry and Behavior, vol. 94, no. 4, pp. 497–502, 2010.
[94] R. Redolat, J. Vidal, M. C. G´ omez, and M. C. Carrasco,
“Eﬀects of acute bupropion administration on locomotor
activity in adolescent and adult mice,” Behavioural Pharma-
cology, vol. 16, no. 1, pp. 59–62, 2005.
[95] P. Bredeloux, I. Dubuc, and J. Costentin, “Comparisons bet-
ween bupropion and dexamphetamine in a range of in vivo
testsexploringdopaminergictransmission,”BritishJournalof
Pharmacology, vol. 150, no. 6, pp. 711–719, 2007.
[96] S. K. Billes and M. A. Cowley, “Catecholamine reuptake
inhibitioncausesweightlossbyincreasinglocomotoractivity
and thermogenesis,” Neuropsychopharmacology, vol. 33, no.
6, pp. 1287–1297, 2008.
[97] H. Tilleman, O. Kofman, L. Nashelsky et al., “Critical role
of the embryonic mid-hindbrain organizer in the behavioral
response to amphetamine and methylphenidate,” Neuro-
science, vol. 163, no. 4, pp. 1012–1023, 2009.
[98] K. M. Smith, D. M. Fagel, H. E. Stevens et al., “Deﬁciency in
inhibitorycorticalinterneuronsassociatedwithhyperactivity
in ﬁbroblast growth factor receptor 1 mutant mice,” Biologi-
cal Psychiatry, vol. 63, no. 10, pp. 953–962, 2008.
[99] M. Niculescu, M. E. Ehrlich, and E. M. Unterwald, “Age-
speciﬁc behavioral responses to psychostimulants in mice,”
Pharmacology Biochemistry and Behavior,v o l .8 2 ,n o .2 ,p p .
280–288, 2005.
[100] K. Minck, P. Danneberg, and F. Knappen, “Eﬀects of psy-
chotropic drugs on exploratory behavior of mice,” Psycho-
pharmacologia, vol. 39, no. 3, pp. 245–257, 1974.
[101] B. S. Starr and M. S. Starr, “Behavioural interactions
involving D1 and D2 dopamine receptors in non-habituated
mice,” Neuropharmacology, vol. 26, no. 6, pp. 613–619,
1987.
[102] E. A. Stone, S. J. Manavalan, Y. Zhang, and D. Quartermain,
“Beta adrenoceptor blockade mimics eﬀects of stress on
motor activity in mice,” Neuropsychopharmacology, vol. 12,
no. 1, pp. 65–71, 1995.
[103] M. I. Damaj, “Inﬂuence of gender and sex hormones on
nicotine acute pharmacological eﬀects in mice,” Journal of
Pharmacology and Experimental Therapeutics, vol. 296, no. 1,
pp. 132–140, 2001.ISRN Pharmacology 11
[104] R. C. MacPhail, J. D. Farmer, K. A. Jarema, and N. Chernoﬀ,
“Nicotineeﬀectsontheactivityofmiceexposedprenatallyto
the nicotinic agonist anatoxin-a,” Neurotoxicology and Tera-
tology, vol. 27, no. 4, pp. 593–598, 2005.
[105] S. J. Wanchoo, M. J. Lee, A. C. Swann, and N. Dafny, “Bila-
teral six-hydroxydopamine administration to PFC prevents
the expression of behavioral sensitization to methylpheni-
date,” Brain Research, vol. 1312, pp. 89–100, 2010.
[106] T. E. Wooters, N. M. Neugebauer, C. R. Rush, and M. T.
Bardo, “Methylphenidate enhances the abuse-related beha-
vioral eﬀects of nicotine in rats: intravenous self-adminis-
tration, drug discrimination, and locomotor cross-sensiti-
zation,” Neuropsychopharmacology, vol. 33, no. 5, pp. 1137–
1148, 2008.
[107] P. B. Yang, A. C. Swann, and N. Dafny, “Chronic methyl-
phenidate modulates locomotor activity and sensory evoked
responses in the VTA and NAc of freely behaving rats,” Neu-
ropharmacology, vol. 51, no. 3, pp. 546–556, 2006.
[108] A. Torres-Rever´ on and D. L. Dow-Edwards, “Repeated
administrationofmethylphenidateinyoung,adolescent,and
mature rats aﬀects the response to cocaine later in adult-
hood,” Psychopharmacology, vol. 181, no. 1, pp. 38–47, 2005.
[109] Y. Itzhak and J. L. Martin, “Eﬀect of the neuronal nitric oxide
synthase inhibitor 7-nitroindazole on methylphenidate-in-
duced hyperlocomotion in mice,” Behavioural Pharmacology,
vol. 13, no. 1, pp. 81–86, 2002.
[110] K.L.Metzger,C.R.Maxwell,Y.Liang,andS.J.Siegel,“Eﬀects
of nicotine vary across two auditory evoked potentials in the
mouse,” Biological Psychiatry, vol. 61, no. 1, pp. 23–30, 2007.
[111] J. M. Phillips, R. S. Ehrlichman, and S. J. Siegel, “Mecamy-
lamine blocks nicotine-induced enhancement of the P20
auditory event-related potential and evoked gamma,” Neu-
roscience, vol. 144, no. 4, pp. 1314–1323, 2007.
[112] E. D. Levin and A. H. Rezvani, “Nicotinic interactions with
antipsychoticdrugs,modelsofschizophreniaandimpactson
cognitive function,” Biochemical Pharmacology, vol. 74, no. 8,
pp. 1182–1191, 2007.
[113] A.H.Rezvani,D.P.Caldwell,andE.D.Levin,“Chronicnico-
tine interactions with clozapine and risperidone and atten-
tional function in rats,” Progress in Neuro-Psychopharma-
cology and Biological Psychiatry, vol. 30, no. 2, pp. 190–197,
2006.
[114] E.D.Levin,A.Petro,andD.P.Caldwell,“Nicotineandcloza-
pine actions on pre-pulse inhibition deﬁcits caused by N-
methyl-D-aspartate (NMDA) glutamatergic receptor block-
ade,” Progress in Neuro-Psychopharmacology and Biological
Psychiatry, vol. 29, no. 4, pp. 581–586, 2005.
[115] E. J. Popke, A. J. Mayorga, C. M. Fogle, and M. G. Paule,
“Eﬀects of acute nicotine on several operant behaviors in
rats,” Pharmacology Biochemistry and Behavior, vol. 65, no.
2, pp. 247–254, 2000.
[116] Y.Tizabi,J.Mastropaolo,C.H.Parketal.,“Bothnicotineand
mecamylamine block dizocilpine-induced explosive jumping
behavior in mice: psychiatric implications,” Psychopharma-
cology, vol. 140, no. 2, pp. 202–205, 1998.
[117] K. Suemaru, K. Yasuda, K. Umeda et al., “Nicotine blocks
apomorphine-induced disruption of prepulse inhibition of
the acoustic startle in rats: possible involvement of central
nicotinic α7r e c e p t o r s , ”British Journal of Pharmacology, vol.
142, no. 5, pp. 843–850, 2004.
[118] H. Javelot, A. Baratta, L. Weiner et al., “Two acute psychotic
episodes after administration of bupropion: a case of invol-
untary rechallenge,” Pharmacy World and Science, vol. 31, no.
2, pp. 238–240, 2009.
[119] T. Javelot, H. Javelot, A. Baratta, L. Weiner, M. Messaoudi,
and P. Lemoine, “Acute psychotic disorders related to bupro-
pion: review of the literature,” Encephale,v o l .3 6 ,n o .6 ,p p .
461–471, 2010.
[120] J. Bailey and S. Waters, “Acute psychosis after bupropion
treatment in a healthy 28-year-old woman,” Journal of the
American Board of Family Medicine, vol. 21, no. 3, pp. 244–
245, 2008.
[121] M. Hahn, T. Hajek, M. Alda, and J. M. Gorman, “Psychosis
induced by low-dose bupropion: sensitization of dopaminer-
gic system by past cocaine abuse?” Journal of Psychiatric Prac-
tice, vol. 13, no. 5, pp. 336–338, 2007.
[122] C. H. Chan, H. C. Liu, and M. C. Huang, “Delirium associ-
ated with concomitant use of low-dose bupropion sustained
release and ﬂuoxetine,” Journal of Clinical Psychopharmacol-
ogy, vol. 26, no. 6, pp. 677–679, 2006.
[123] T. S. Wang, I. S. Shiah, C. B. Yeh, and C. C. Chang, “Acute
psychosis following sustained release bupropion overdose,”
Progress in Neuro-Psychopharmacology and Biological Psychi-
atry, vol. 29, no. 1, pp. 149–151, 2005.
[124] M. Kraemer, J. Uekermann, J. Wiltfang, and B. Kis, “Methyl-
phenidate-induced psychosis in adult attention-deﬁcit/hyp-
eractivity disorder: report of 3 new cases and review of the
literature,” Clinical Neuropharmacology, vol. 33, no. 4, pp.
204–206, 2010.
[125] C. Greiner, E. Enß, and E. Haen, “Drug-induced psychosis
after intake of a modiﬁed-release formulation of methylphe-
nidate,” Psychiatrische Praxis, vol. 36, no. 2, pp. 89–91, 2009.
[126] A. D. Mosholder, K. Gelperin, T. A. Hammad, K. Phelan,
and R. Johann-Liang, “Hallucinations and other psychotic
symptomsassociatedwiththeuseofattention-deﬁcit/hyper-
activity disorder drugs in children,” Pediatrics,vol. 123, no. 2,
pp. 611–616, 2009.
[127] R. G. Ross, “Psychotic and manic-like symptoms during
stimulant treatment of attention deﬁcit hyperactivity disor-
der,”AmericanJournalofPsychiatry,vol.163,no.7,pp.1149–
1152, 2006.
[128] C. Curran, N. Byrappa, and A. McBride, “Stimulant psy-
chosis: systematic review,” British Journal of Psychiatry, vol.
185, pp. 196–204, 2004.
[129] M.Bruggisser,A.Ceschi,M.Bodmer,M.F.Wilks,H.Kupfer-
schmidt, and M. E. Liechti, “Retrospective analysis of stim-
ulant abuse cases reported to the Swiss Toxicological Infor-
mation Centre during 1997—2009,” Swiss Medical Weekly,
vol. 140, article w13115, 2010.
[130] S. E. McCallum, A. C. Collins, R. Paylor, and M. J. Marks,
“Deletion of the beta 2 nicotinic acetylcholine receptor sub-
unit alters development of tolerance to nicotine and elimi-
nates receptor upregulation,” Psychopharmacology, vol. 184,
no. 3-4, pp. 314–327, 2006.
[131] L. P. Dwoskin, A. S. Rauhut, K. A. King-Pospisil, and M.
T. Bardo, “Review of the pharmacology and clinical proﬁle
of bupropion, an antidepressant and tobacco use cessation
agent,” CNS Drug Reviews, vol. 12, no. 3-4, pp. 178–207,
2006.
[132] S. K. Billes and M. A. Cowley, “Inhibition of dopamine and
norepinephrine reuptake produces additive eﬀects on energy
balance in lean and obese mice,” Neuropsychopharmacology,
vol. 32, no. 4, pp. 822–834, 2007.
[133] C. E. John and S. R. Jones, “Voltammetric characterization of
the eﬀect of monoamine uptake inhibitors and releasers on
dopamine and serotonin uptake in mouse caudate-putamen
and substantia nigra slices,” Neuropharmacology, vol. 52, no.
8, pp. 1596–1605, 2007.12 ISRN Pharmacology
[134] N. Sidhpura, P. Redfern, H. Rowley, D. Heal, and S. Won-
nacott, “Comparison of the eﬀects of bupropion and nico-
tine on locomotor activation and dopamine release in vivo,”
Biochemical Pharmacology, vol. 74, no. 8, pp. 1292–1298,
2007.
[135] O. T. Ukairo, S. Ramanujapuram, and C. K. Surratt, “Fluctu-
ation of the dopamine uptake inhibition potency of cocaine,
but not amphetamine, at mammalian cells expressing the
dopamine transporter,” Brain Research, vol. 1131, no. 1, pp.
68–76, 2007.
[136] P. Weikop, J. Kehr, and J. Scheel-Kr¨ uger, “Reciprocal eﬀects
of combined administration of serotonin, noradrenaline and
dopamine reuptake inhibitors on serotonin and dopamine
levels in the rat prefrontal cortex: the role of 5-HT1A recep-
tors,” Journal of Psychopharmacology, vol. 21, no. 8, pp. 795–
804, 2007.
[137] L. M. Marubio, A. M. Gardier, S. Durier et al., “Eﬀects of
nicotine in the dopaminergic system of mice lacking the
alpha4 subunit of neuronal nicotinic acetylcholine recep-
tors,” European Journal of Neuroscience,v o l .1 7 ,n o .7 ,p p .
1329–1337, 2003.
[138] M. R. Picciotto, M. Zoli, R. Rimondini et al., “Acetylcholine
receptors containing the β2 subunit are involved in the rein-
forcingproperties ofnicotine,” Nature,vol.391, no.6663,pp.
173–177, 1998.
[139] S. R. Grady, N. M. Meinerz, J. Cao et al., “Nicotinic agonists
stimulate acetylcholine release from mouse interpeduncular
nucleus: a function mediated by a diﬀerent nAChR than
dopamine release from striatum,” Journal of Neurochemistry,
vol. 76, no. 1, pp. 258–268, 2001.
[140] J. E. Rose and W. A. Corrigall, “Nicotine self-administration
in animals and humans: similarities and diﬀerences,” Psycho-
pharmacology, vol. 130, no. 1, pp. 28–40, 1997.